This on demand webinar provides a detailed overview of how a global CDMO supports cell and gene therapy programs from early development through commercial manufacturing. In the session, Joseph Garrity, Executive Director of Portfolio Management at Lonza Specialized Modalities, explains how the organization approaches cell therapy, viral vector manufacturing, mRNA manufacturing, and microbial technologies. The discussion focuses on practical capabilities, operating experience, and infrastructure that supports clinical and commercial supply.
The webinar highlights CDMO services for autologous and allogeneic cell therapy, including T cell and emerging allogeneic platforms, as well as viral vector manufacturing for AAV and lentivirus. The presentation explains how process development connects to GMP manufacturing to support technology transfer, scale up, and long term supply planning. Viewers gain a clear understanding of how a CDMO applies experience across different cell types, vectors, and unit operations.
A significant portion of the webinar is dedicated to global manufacturing capacity for cell and gene therapy. The session reviews active GMP sites in the United States, Europe, and Asia, including facilities that support both clinical and commercial production. The speaker explains why regional manufacturing footprints matter for therapies with fresh starting material, short shelf life, or regional patient access requirements.
The webinar also covers mRNA development and manufacturing capabilities that were expanded following large scale vaccine production. This includes discussion of segregated facilities, clinical manufacturing services, and planning for commercial scale. The content is relevant for companies evaluating CDMO partners for mRNA therapeutics, vaccines, and in vivo CAR T programs that require reliable supply chain execution.
This webinar is intended for professionals involved in the development and manufacturing of advanced therapies. It is particularly relevant for leaders and teams responsible for cell and gene therapy strategy, process development, technical operations, and CMC planning. The target audience includes biotech and pharmaceutical executives, manufacturing and process development leaders, CMC and technical operations teams, supply chain and program management professionals, and decision makers evaluating CDMO partners for clinical or commercial programs.
Complete the form on this page to watch the full webinar and hear a detailed discussion of CDMO capabilities for cell therapy, viral vector manufacturing, and mRNA development and manufacturing.
